Bavarian Nordic A/S/DKr BAVA
08:00
10:00
12:00
13:55
15:55
1D1W1MYTD1Y5YMAX
About Bavarian Nordic A/S
Bavarian Nordic A/S is a biotechnology company based in Denmark, specializing in the development, manufacturing, and commercialization of vaccines for infectious diseases and cancer immunotherapies. The company’s core products include vaccines such as Jynneos/Imvanex/Imvamune for smallpox and monkeypox, as well as the Rabipur/RabAvert rabies vaccine. Established in 1994, Bavarian Nordic supports its global operations through its headquarters in Hellerup, Denmark, and production facilities in Kvistgaard. The company distinguishes itself through its proprietary MVA-BN technology platform, which enhances vaccine efficacy and safety, offering a strategic advantage in vaccine development and production.
Ticker
DKr BAVA
Sector
Primary listing
CSE
Employees
1,692
Headquarters
Hellerup, Denmark
Website
BAVA Metrics
BasicAdvanced
kr 14B
10.36
kr 17.60
1.09
-
Price and volume
Market cap
kr 14B
Beta
1.09
52-week high
kr 243.70
52-week low
kr 123.30
Average daily volume
264K
Financial strength
Current ratio
4.217
Quick ratio
2.622
Long term debt to equity
0.663
Total debt to equity
1.017
Interest coverage (TTM)
167.44%
Profitability
EBITDA (TTM)
1,653.593
Gross margin (TTM)
49.20%
Net profit margin (TTM)
22.03%
Operating margin (TTM)
16.58%
Effective tax rate (TTM)
23.63%
Revenue per employee (TTM)
kr 3,690,000
Management effectiveness
Return on assets (TTM)
4.41%
Return on equity (TTM)
11.33%
Valuation
Price to earnings (TTM)
10.361
Price to revenue (TTM)
2.279
Price to book
1.12
Price to tangible book (TTM)
2.08
Price to free cash flow (TTM)
10.442
Free cash flow yield (TTM)
9.58%
Free cash flow per share (TTM)
17.463
Growth
Revenue change (TTM)
9.23%
Earnings per share change (TTM)
39.68%
3-year revenue growth (CAGR)
25.61%
10-year revenue growth (CAGR)
19.86%
3-year earnings per share growth (CAGR)
52.80%
10-year earnings per share growth (CAGR)
23.69%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Bavarian Nordic A/S stock?
Bavarian Nordic A/S (BAVA) has a market cap of DKr14B as of March 17, 2026.
What is the P/E ratio for Bavarian Nordic A/S stock?
The price to earnings (P/E) ratio for Bavarian Nordic A/S (BAVA) stock is 10.36 as of March 17, 2026.
Does Bavarian Nordic A/S stock pay dividends?
No, Bavarian Nordic A/S (BAVA) stock does not pay dividends to its shareholders as of March 17, 2026.
When is the next Bavarian Nordic A/S dividend payment date?
Bavarian Nordic A/S (BAVA) stock does not pay dividends to its shareholders.
What is the beta indicator for Bavarian Nordic A/S?
Bavarian Nordic A/S (BAVA) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.